Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Namwiwat Medical PCLBKK:NAM -0.59%35 Debt-to-EBITDA is 2.88 as of Mar. 2026, which is 132% above its 10-year median of 1.24. GuruFocus rates BKK:NAM with a GF Score™ of 35/100 and a GF Value™ of ฿6.84 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 472 Medical Devices & Instruments companies, Namwiwat Medical PCL ranks worse than 63.98% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Namwiwat Medical PCL's Debt-to-EBITDA or its related term are showing as below:
BKK:NAM'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.78 Med: 1.24 Max: 2.47
Current: 2.47
During the past 6 years, the highest Debt-to-EBITDA Ratio of Namwiwat Medical PCL was 2.47. The lowest was 0.78. And the median was 1.24.
BKK:NAM's Debt-to-EBITDA is ranked worse than 63.98% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 1.64
vs BKK:NAM: 2.47
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Namwiwat Medical PCL Debt-to-EBITDA Related Terms
Namwiwat Medical PCL Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Namwiwat Medical PCL's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:NAM vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Namwiwat Medical PCL's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Namwiwat Medical PCL Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Namwiwat Medical PCL's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Namwiwat Medical PCL's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Namwiwat Medical PCL (BKK:NAM) has a Debt-to-EBITDA of 2.88 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Namwiwat Medical PCL. This is 132% above median its historical median of 1.24. Over the past decade, Namwiwat Medical PCL's Debt-to-EBITDA has ranged from 0.78 to 2.47. According to the industry distribution chart, Namwiwat Medical PCL ranks #302 out of 472 companies in the Medical Devices & Instruments industry, placing it in the top 64%.
Is Namwiwat Medical PCL's Debt-to-EBITDA too high?
Namwiwat Medical PCL's current Debt-to-EBITDA of 2.88 is 132% above median its 10-year median of 1.24. Over the past 10 years, this metric has ranged from a low of 0.78 to a high of 2.47. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.64. Namwiwat Medical PCL's value of 2.88 is 75.6% above this industry median. Based on the distribution chart, Namwiwat Medical PCL ranks #302 out of 472 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Namwiwat Medical PCL has a GF Score™ of 35/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Namwiwat Medical PCL's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Namwiwat Medical PCL ranks #302 out of 472 companies for Debt-to-EBITDA. This places Namwiwat Medical PCL in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. Namwiwat Medical PCL's value of 2.88 is 75.6% above this benchmark. Historically, Namwiwat Medical PCL's own Debt-to-EBITDA has ranged from 0.78 to 2.47 over the past decade. While the company's 10-year median is 1.24 vs. the industry median of 1.64, Namwiwat Medical PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.64, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Namwiwat Medical PCL's current Debt-to-EBITDA of 2.88 is 75.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Namwiwat Medical PCL. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Namwiwat Medical PCL's current Debt-to-EBITDA is 2.88, which is 132% above median its own 10-year median of 1.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Namwiwat Medical PCL stock overvalued right now?
Based on GuruFocus' analysis, Namwiwat Medical PCL (BKK:NAM) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿6.84, compared to a current price of ฿3.36 — trading 50.9% below its estimated fair value. The current Debt-to-EBITDA is 2.88, which is 132% above median its 10-year median of 1.24 and 75.6% above the Medical Devices & Instruments industry median of 1.64. Namwiwat Medical PCL's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Namwiwat Medical PCL (BKK:NAM), the current Debt-to-EBITDA is 2.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Namwiwat Medical PCL (BKK:NAM) Overvalued in 2026?
Based on GuruFocus' analysis, Namwiwat Medical PCL stock appears to be undervalued.
The current stock price of ฿3.36 is trading 50.9% below its estimated GF Value™ of ฿6.84.
GuruFocus considers Namwiwat Medical PCL to be Significantly Undervalued.
Key valuation signals for BKK:NAM:
Debt-to-EBITDA: 2.88 (132% above median its 10-year median of 1.24)
GF Value™: ฿6.84 vs. price of ฿3.36 (50.9% below fair value)
Industry Position: 75.6% above the Medical Devices & Instruments median (#302 of 472)
No single metric tells the full story. See the BKK:NAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Namwiwat Medical Corp PCL operates a manufacturing business, importing and distributing Medical tools and equipment for cleaning and disinfecting medical equipment in hospitals and nursing homes in accordance with public health standards. The Group has a total of three reporting segments as follows: Medical equipment manufacturing and distribution segment; Medical supplies manufacturing and distribution segment; CSSD disinfection Medical equipment maintenance services segment, and waste services segment. The Group operates its business in one geography, only in Thailand.
35GF Score
Get the complete analysis for BKK:NAM
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:NAM has been successfully added to your 
